Balloon pulmonary angioplasty – efficient therapy of chronic thromboembolic pulmonary hypertension in the patient with advanced sarcoidosis – a case report

Andrzej Labyk1*, Dominik Wretowski1, Sabina Zybińska-Oksiutowicz1, Aleksandra Furdyna1, Katarzyna Ciesielska1, Dorota Piotrowska-Kownacka2, Olga Dziakowska-Diduch1, Barbara Lichodziejewska1, Andrzej Biederman3, Piotr Pruszczynski1 and Marek Roik1

Abstract

Background: Approximately a quarter of patients with advanced sarcoidosis develop pulmonary hypertension (PH), which affects their prognosis. We report unusual case of confirmed chronic thromboembolic pulmonary hypertension (CTEPH) in a patient with stage IV sarcoidosis successfully treated with balloon pulmonary angioplasty (BPA).

Case presentation: A 65 years old male with a history of colitis ulcerosa, and pulmonary sarcoidosis diagnosed in 10 years before, on long term oral steroids, with a history of deep vein thrombosis and acute pulmonary embolism chronically anticoagulated was referred to our center due to severe dyspnea. On admission he presented WHO functional class IV, mean pulmonary artery pressure (mPAP) in right heart catheterization (RHC) was elevated to 54 mmHg. Diagnosis of CTEPH was definitely confirmed with typical V/Q scan, and with selective pulmonary angiography (PAG) complete by intravascular imaging (intravascular ultrasound, optical coherent tomography). The patient was deemed inoperable by CTEPH team and two sessions of BPA with multimodal approach resulted in significant clinical and haemodynamical improvement to WHO class II and mPAP decrease to 27 mmHg.

Conclusions: Balloon pulmonary angioplasty, rapidly developing method of treatment of inoperable CTEPH patients, is also extremely useful therapeutic tool in complex PH patients.

Keywords: Sarcoidosis, Chronic thromboembolic pulmonary hypertension, Balloon pulmonary angioplasty

Background

Approximately 26% of patients with advanced pulmonary sarcoidosis may develop pulmonary hypertension (PH), which is related with poor prognosis [1, 2]. According to current guidelines, patients with suspected PH should undergo detailed diagnostic workup and differential diagnosis among others should include chronic lung diseases leading to hypoxia and chronic thromboembolic pulmonary hypertension (CTEPH) [3]. We report an unusual challenging case of CTEPH in a patient with stage IV sarcoidosis.

Case presentation

A 65 years old male with history of colitis ulcerosa, and advanced sarcoidosis diagnosed 10 years before, on oral steroids was admitted to our department due to exertional dyspnea and right ventricular (RV) heart failure progressing since last 12 months to functional class IV. Two years earlier, he experienced the first severe decompensation of right heart function. At that time PH was diagnosed on echocardiography. RV to left ventricle (LV) ratio exceeded one (RV:LV - 39/32 mm); peak systolic tricuspid regurgitation gradient (TRPG) was 75 mmHg, and decreased tricuspid annular plane systolic excursion.
(TAPSE) 15 mm indicated significant pressure overload and RV systolic dysfunction. Chest computed tomography (CT) revealed sarcoidosis progression, however no pulmonary thromboemboli were detected. After typical heart failure treatment with diuretics, ACE inhibitors, and steroid dose increase the patient improved and he was discharged home in a good clinical condition in WHO functional class II, with the diagnosis of PH due to sarcoidosis stage IV. One year later, due to acute dyspnea, worsening of RV function and unilateral leg swelling he underwent another chest CT, which this time showed fresh thrombi in the left segmental upper lobe pulmonary artery. Moreover, acute deep vein thrombosis was detected with lower limb compression ultrasound. Long term oral anticoagulation with rivaroxaban was started. Two years later the patient was referred to our center due to progressive functional deterioration. On admission he was in WHO functional class IV, saturation on room air was 85%, blood pressure 120/80 mmHg, heart rate 90 beats per minute. Mild peripheral edema was present. Distance covered in 6 min walk test (6MWT) was 100 m with desaturation to 77%. Plasma natriuretic peptide (NT-pro-BNP) concentration was elevated to 6239 pg/ml (normal range <125 pg/ml). Echocardiography showed severe RV pressure overload with TRPG 95 mmHg, dilatation of both right atrium and ventricle. Preserved morphology and function of LV was observed. Chest CT scan showed signs of advanced interstitial lung fibrosis (Fig. 1a) and calcified mediastinal lymph nodes (Fig. 1b). However, organized thrombi in both pulmonary were also detected (Fig. 1c and d). At that time multifactorial etiology of PH was considered: sarcoidosis with secondary PH and local in situ thrombosis, or CTEPH in a patient with stage IV sarcoidosis, and with deep vein thrombosis in the past. Lung perfusion scan with SPECT/CT showed bilateral perfusion defects which strongly suggested thromboembolic component of PH. Right heart catheterization (RHC) followed by selective pulmonary angiography (PAG) showed mean pulmonary artery pressure (mPAP) of 54 mmHg. Pulmonary artery wedge pressure (PAWP) was 6 mmHg and pulmonary vascular resistance (PVR) was 13.5 Wood Units. Selective PAG confirmed chronic thromboembolic lesions suggestive of CTEPH – left upper lobe artery occlusion, intravascular webs in right pulmonary artery (Fig. 2a). After experienced cardiac surgeon consultation, the patient was deemed inoperable due to advanced, sarcoidosis - related lung changes and propable complications regarding the use of extracorporeal circulation. He was finally qualified for balloon pulmonary angioplasty (BPA).

BPA procedures were performed according the previously published protocol [4]. Importantly, in order to confirm intraluminal localization of thromboembolic
lesions intravascular imaging with optical coherence tomography (OCT) and intravascular ultrasound (IVUS) were performed. It allowed to definitely confirm organized thrombi (Fig. 2a – white arrow, 2C, 2D). With the use of pressure catheter we assessed hemodynamic significance of intrapulmonary lesions (Fig. 2b). Pulmonary pressure ratio (PPR, the ratio of the pressure distal to the lesion (Pd) divided by the pressure proximal to the lesion (Pp)) was assessed to optimize the BPA procedure and to minimize potential complications such as reperfusion pulmonary injury (RPI). PPR in arteries A9 and A10 was 0.19 and 0.22 – which suggested functional occlusion of both arteries. After simultaneous inflation of balloon catheters - “kissing balloon” technique (4.0x20mm and 4.0x27mm respectively), followed by proximal optimization with 7.0x30mm balloon catheter resulted in PPR 0.63 in A9 and 0.65 in A10 (Fig. 3, part A and D – green curve marking distal pressure). There were no periprocedural complications. Mean PAP after the first BPA procedure decreased from 52 mmHG to 40 mmHg. The second BPA session was performed 3 weeks later (left pulmonary artery), also without complications. Both procedures (3 segmental lesions in total) resulted in further hemodynamic and functional improvement, with mPAP drop to 27 mmHg at 12 months follow – up. Patient was still in functional class II WHO, echocardiography and 6MWT showed further improvement in clinical condition and RV function (Table 1).

Discussion and conclusions
Sarcoidosis related PH as is predominantly caused severe lung fibrosis or by compression of pulmonary arteries by mediastinal fibrosis and lymphadenopathy [1, 2, 5]. Pulmonary artery stenting was reported to be efficient in the treatment of pulmonary arteries compression in advanced sarcoidosis [5], while pharmacology with sildenafil or other PH specific drugs are of very limited short term efficacy [6, 7].

Presented case is probably one of the first available reports with initially suspected sarcoidosis related PH, which eventually was verified by pulmonary angiography and multimodal intravascular assessment as CTEPH. There are no data on optimal treatment in such challenging patients. After being deemed inoperable due to advanced sarcoidosis resulting in severe lung alterations, the patient was qualified to BPA procedure. Percutaneous catheter based method, is a rapidly developing therapeutic method for CTEPH patients. There is a growing evidence that in expert centers it is safe and effective, allowing normalization or near normalization of
mPAP in majority of treated cases [4, 8–13]. In our institution we have started BPA program in inoperable CTEPH in 2014. BPA procedures are performed according to the previously described protocol [4] with the use of pressure catheter, and in selected cases with OCT/IVUS intravascular imaging. Our data indicate that this technique is safe and effective also in CTEPH high risk patients with severe comorbidities [14]. We are convinced that multimodal approach not only allowed to confirm CTEPH definitely in the patient with advanced sarcoidosis, but it also allowed to treat him and successfully and safely. We performed angioplasties of selected thromboembolic lesions, which were proved to be hemodynamically significant in multimodal assessment. Such fast improvement was also observed in other CTEPH patients treated with BPA. Based on our experience, it is related with initial treatment of the lesions in segmental arteries of lower lobes. In presented case, specific drug therapy (riociguat) was not available at that time. Patient was on sildenafi (25 mg t.i.d.) and initial mPAP decreased only by 2 mmHg (54 mmHg in initial RHC versus 52 mmHg before first BPA session). Thus, only two BPA sessions resulted in mPAP reduction and significant clinical improvement. We think that BPA became a real therapeutic option in CTEPH patients, who are not candidates for surgery.

Table 1 Clinical and hemodynamical assessment before and after 2 BPA sessions

|                                | Before treatment | At 12 months follow-up |
|--------------------------------|------------------|------------------------|
| WHO functional class           | IV               | II                     |
| NT-pro-BNP level (pg/ml)       | 6239             | 281                    |
| 6MWT distance (m)              | 100              | 405                    |
| TRPG (mmHg)                    | 95               | 31                     |
| RVSP (mmHg)                    | 102              | 53                     |
| TAPSE (mm)                     | 14               | 20                     |
| AcT (ms)                       | 63               | 100                    |
| mPAP (mmHg)                    | 54               | 27                     |
| CI (l/min/m²)                  | 2.08             | 3.34                   |
| RAP (mmHg) systolic/diastolic/mean | 14/10/9 | 5/3/1                  |
| PVR (Wood Units)               | 13.5             | 3.7                    |

NT-pro-BNP natriuretic peptide concentration, 6MWT 6 min walk test, TRPG tricuspid regurgitation peak gradient, RVSP right ventricle systolic pressure, TAPSE tricuspid annular plane excursion, AcT acceleration time, mPAP mean pulmonary artery pressure, CI cardiac index, RAP right atrial pressure, PVR pulmonary vascular resistance, BPA balloon pulmonary angioplasty

Abbreviations

6MWT: 6 min walk test; AcT: Acceleration time; BPA: Balloon pulmonary angioplasty; CT: Computed tomography; CTEPH: Chronic thromboembolic pulmonary hypertension; IVUS: Intravascular ultrasound; LV: Left ventricle; mPAP: Mean pulmonary artery pressure; NT-pro-BNP: Natriuretic peptide concentration; OCT: Optical coherent tomography; PAG: Pulmonary angiography; PAWP: Pulmonary artery wedge pressure; PH: Pulmonary hypertension; PPR: Pulmonary pressure ratio; PVR: Pulmonary vascular resistance
vascular resistance; RAP: Right atrial pressure; RHC: Right heart catheterization; RPI: Reperfusion pulmonary injury; RV: Right ventricle; RVP: Right ventricle systolic pressure; SPECT: Single-photon emission computed tomography; TAPSE: Tricuspid annular plane excursion; TRPG: Tricuspid regurgitation peak gradient

Funding
The authors declare that there was no funding regarding this manuscript.

Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

Authors’ contributions
AL – analysis and interpretation of patient’s data, second operator in BPA procedures, leading contribution in writing the manuscript. DW, MR – first operators in BPA procedures, data analysis and interpretation, supervision, contribution in writing the manuscript. SZO, AF, KC – diagnostic work-up, follow-up, data collection. DPK – radiology studies assessment. ODD, BL – echocardiography assessment. AB – cardiac surgeon, consulted the patient. PP - contribution in writing the manuscript, supervision. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Written informed consent for publication in BMC Pulmonary Medicine was obtained.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1. Center for Diagnostics and Treatment of Venous Thromboembolism, Department of Internal Medicine and Cardiology, Warsaw Medical University, Infant Jesus Hospital, Lindleya Street 4, 02-005 Warsaw, Poland. 2. Department of Radiology, Infant Jesus Hospital, Lindleya Street 4, 02-005 Warsaw, Poland. 3. Cardiac Surgery Department Medicover Hospital, Rzeczypospolitej 5 Avenue, 02-972 Warsaw, Poland.

Received: 9 March 2018 Accepted: 20 July 2018
Published online: 16 August 2018

References
1. Boucly A, Cottin V, Nunes H, et al. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. Eur Respir J. 2017. https://doi.org/10.1183/13993003.00465-2017.

2. Baughman RP, Shiobin OA. Treatment of sarcoidosis-associated pulmonary hypertension: so close, and yet so far. Eur Respir J. 2017; https://doi.org/10.1183/13993003.01725-2017.

3. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119.

4. Roik M, Wretowski D, Labyk A, et al. Refined balloon pulmonary angioplasty driven by combined assessment of intra-arterial anatomy and physiology – Multimodal approach to treated lesions in patients with non-operable distal chronic thromboembolic pulmonary hypertension – Technique, safety and efficacy of 50 consecutive angioplasties. Int J Cardiol. 2016;203:228–35.

5. Hamilton-Craig CR, Slaughter R, McNeil K, et al. Improvement after angioplasty and stenting of pulmonary arteries due to sarcoid mediastinal fibrosis. Heart Lung Circ. 2009;18(3):222–5.

6. Toonkel RL, Borczuk AC, Pearson GD, et al. Sarcoidosis-associated fibrosing mediastinitis with resultant pulmonary hypertension: a case report and review of the literature. Respiration. 2010;79(4):341–5.

7. Kapczak A, Sztrumowicz M, Burakowska B, et al. Sarcoidosis-associated pulmonary hypertension treated with sildenafil – a case report. Adv Respir Med. 2017;78(5):258–63.

8. Mizoguchi H, Ogawa A, Munemasa M, et al. Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv. 2012;5(6):748–55.

9. Katoaka M, Inami T, Hayashida K, et al. Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv. 2012;5:756–62.

10. Sugimura K, Fukumoto Y, Satoh K, et al. Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension. Circ J. 2012;76(2):485–8.

11. Inami T, Katoaka M, Shimura N, et al. Pressure-wire-guided percutaneous transluminal pulmonary angioplasty: a breakthrough in catheter-interventional therapy for chronic thromboembolic pulmonary hypertension. JACC Cardiovasc Interv. 2014;7(11):1197–306.

12. Roik M, Wretowski D, Labyk A, et al. Optical coherence tomography of inoperable chronic thromboembolic pulmonary hypertension treated with refined balloon pulmonary angioplasty. Pol Arch Med Wewn. 2014;124(12):742–3.

13. Roik M, Wretowski D, Roswiński O, et al. Refined balloon pulmonary angioplasty in inoperable chronic thromboembolic pulmonary hypertension – a multi-modality approach to the treated lesion. Int J Cardiol. 2014;177(3):e139–41.

14. Roik M, Wretowski D, Labyk A, et al. Refined balloon pulmonary angioplasty - a therapeutic option in very elderly patients with chronic thromboembolic pulmonary hypertension. J Interv Cardiol. 2017;30(3):249–55.